Research Summary

My research program is focused on imaging cancer using MRI and novel PET tracers. At UCSF, I have developed the gallium-68 DOTA-TOC imaging program for neuroendocrine tumor staging, and am the principle investigator on the FDA IND. I have also successfully brought Ga-68 PSMA imaging to UCSF and am currently drafting the IND submission to allow for the evaluation of the clinical use of this agent. I am interested in using somatostatin receptor and PSMA based PET agents in order to distinguish neuroendocrine prostate cancer from adenocarcinoma. Additionally, I believe that the combination of MR and PET parameters will aid in the staging of cancers. Most straightforward is a study we are carrying out in low risk prostatectomy patients where we are evaluating the use of PET/MRI using Ga-68 PSMA and MR imaging of the primary tumor. In the setting of patients with metastatic disease, PET/MRI will likely have an even more important role, as response to treatment will change uptake of non-FDG tracers in ways that are not immediately clear and intepretation will likely rely on changes in MR imaging parameters such as diffusion weighted imaging (DWI).

Research Funding

  • July 1, 2019 - June 30, 2024 - MELT: Modulation of PSMA Expression for Lutetium Therapy, Principal Investigator. Sponsor: NIH/NCI, Sponsor Award ID: R01CA235741
  • March 6, 2017 - February 28, 2022 - Qualification and Harmonization of PET/MRI for Cancer Clinical Trials, Principal Investigator. Sponsor: NIH/NCI, Sponsor Award ID: R01CA212148
  • June 1, 2019 - April 30, 2021 - Immunogenic Priming with Lu-PSMA Targeted Therapy in Advanced Prostate Cancer, Co-Principal Investigator. Sponsor: NIH/NCI, Sponsor Award ID: R01CA229354
  • July 1, 2019 - June 30, 2024 - MELT: Modulation of PSMA Expression for Lutetium Therapy, Principal Investigator. Sponsor: NIH/NCI, Sponsor Award ID: R01CA235741

Education

Duke University, Durham, NC, BA/BS, 6/2001, Biology, Economics
Stanford University, MD, 6/2007 Medicine
Kaiser San Francisco, 6/2008, Internal Medicine
University of California, San Francisco, 6/2012, Diagnostic Radiology Residency
Stanford University, 6/2013, Body MRI/nuclear medicine Fellowship

Honors & Awards

  • 2001
    Summa Cum Laude, Duke University
  • 2001
    Phi Beta Kappa, Duke University
  • 2006
    Trainee Research Prize, Radiological Society of North America
  • 2007
    W. S. Moore Award, Nominee, International Society of Magnetic Resonance in Medicine
  • 2011
    Magnum Cum Laude Merit Award, International Society of Magnetic Resonance in Medicine
  • 2012
    Roentgen Resident/Fellow Research Award, Radiological Society of North America
  • 2012
    Alexander Margulis Society Excellence in Research Award, UCSF
  • 2014
    Wylie J. Dodds Research Award, Society of Abdominal Radiology

Selected Publications

  1. Marzella L, Czernin J, Hope T. Perspectives on Radiopharmaceutical Agents from the FDA: A Conversation between Lou Marzella, Johannes Czernin, and Thomas Hope. J Nucl Med. 2021 Jul 01; 62(7):881-883.  View on PubMed
  2. Salavati A, Gencturk M, Koksel Y, Schik AN, Carroll PR, Feng FY, Rowe SP, Lawhn-Heath C, Hope TA, Froelich JW. A bicentric retrospective analysis of clinical utility of 18F-fluciclovine PET in biochemically recurrent prostate cancer following primary radiation therapy: is it helpful in patients with a PSA rise less than the Phoenix criteria? Eur J Nucl Med Mol Imaging. 2021 Jun 06.  View on PubMed
  3. Afaq A, Faul D, Chebrolu VV, Wan S, Hope TA, Haibach PV, Bomanji J. Pitfalls on PET/MRI. Semin Nucl Med. 2021 May 18.  View on PubMed
  4. Chu CE, Alshalalfa M, Sjöström M, Zhao SG, Liu Y, Chou J, Herlemann A, Mahal B, Kishan AU, Spratt DE, Cooperberg M, Small E, Wong A, Porten S, Hope TA, Ross AE, Davicioni E, Nguyen P, Karnes RJ, Carroll PR, Schaeffer E, Feng FY. Prostate-specific Membrane Antigen and Fluciclovine Transporter Genes are Associated with Variable Clinical Features and Molecular Subtypes of Primary Prostate Cancer. Eur Urol. 2021 Jun; 79(6):717-721.  View on PubMed
  5. Koontz BF, Hope TA. More Answers and More Questions About Radiotherapy for Metastatic Prostate Cancer. JAMA Oncol. 2021 Apr 01; 7(4):563-564.  View on PubMed
  6. Fishbein L, Del Rivero J, Else T, Howe JR, Asa SL, Cohen DL, Dahia PLM, Fraker DL, Goodman KA, Hope TA, Kunz PL, Perez K, Perrier ND, Pryma DA, Ryder M, Sasson AR, Soulen MC, Jimenez C. The North American Neuroendocrine Tumor Society Consensus Guidelines for Surveillance and Management of Metastatic and/or Unresectable Pheochromocytoma and Paraganglioma. Pancreas. 2021 Apr 01; 50(4):469-493.  View on PubMed
  7. Lawhn-Heath C, Salavati A, Behr SC, Rowe SP, Calais J, Fendler WP, Eiber M, Emmett L, Hofman MS, Hope TA. Prostate-specific Membrane Antigen PET in Prostate Cancer. Radiology. 2021 Mar 30; 202771.  View on PubMed
  8. Bucknor MD, Hope TA. Reply: Disparities in PET Imaging of Prostate Cancer at a Tertiary Academic Medical Center. J Nucl Med. 2021 May 10; 62(5):748.  View on PubMed
  9. Jha A, Taieb D, Carrasquillo JA, Pryma DA, Patel M, Millo C, de Herder WW, Del Rivero J, Crona J, Shulkin BL, Virgolini I, Chen AP, Mittal BR, Basu S, Dillon JS, Hope TA, Mari Aparici C, Iagaru A, Hicks RJ, Avram AM, Strosberg JR, Civelek AC, Lin FI, Pandit-Taskar N, Pacak K. High-specific-activity 131I-MIBG vs 177Lu-DOTATATE targeted radionuclide therapy for metastatic pheochromocytoma and paraganglioma. Clin Cancer Res. 2021 Mar 08.  View on PubMed
  10. Hope TA, Graves CE, Calais J, Ehman E, Johnson GB, Thompson D, Aslam M, Duh QY, Gosnell J, Shen W, Roman S, Sosa JA, Kluijfhout W, Seib CS, Villanueva-Meyer J, Pampaloni MH, Suh I. Accuracy of 18F-fluorocholine PET for the detection of parathyroid adenomas: prospective single center study. J Nucl Med. 2021 Mar 05.  View on PubMed
  11. Ceci F, Oprea-Lager DE, Emmett L, Adam JA, Bomanji J, Czernin J, Eiber M, Haberkorn U, Hofman MS, Hope TA, Kumar R, Rowe SP, Schwarzenboeck SM, Fanti S, Herrmann K. E-PSMA: the EANM standardized reporting guidelines v1.0 for PSMA-PET. Eur J Nucl Med Mol Imaging. 2021 05; 48(5):1626-1638.  View on PubMed
  12. Hope TA, Calais J. PSMA-targeted radiopharmaceutical therapy in patients with metastatic castration-resistant prostate cancer. Lancet. 2021 Feb 27; 397(10276):768-769.  View on PubMed
  13. Murthy V, Sonni I, Jariwala N, Juarez R, Reiter RE, Raman SS, Hope TA. The Role of PSMA PET/CT and PET/MRI in the Initial Staging of Prostate Cancer. Eur Urol Focus. 2021 Mar; 7(2):258-266.  View on PubMed
  14. Sartor O, Hope TA, Calais J, Fendler WP. Oliver Sartor Talks with Thomas A. Hope, Jeremie Calais, and Wolfgang P. Fendler About FDA Approval of PSMA. J Nucl Med. 2021 02; 62(2):146-148.  View on PubMed
  15. Tranel J, Feng FY, James SS, Hope TA. Effect of microdistribution of alpha and beta-emitters in targeted radionuclide therapies on delivered absorbed dose in a GATE model of bone marrow. Phys Med Biol. 2021 01 29; 66(3):035016.  View on PubMed
  16. Whitman J, Allen IE, Bergsland EK, Suh IA, Hope TA. Assessment and comparison of fluorocholine PET and sestamibi scans in identifying parathyroid adenomas: a meta-analysis. J Nucl Med. 2021 Jan 15.  View on PubMed
  17. Calais J, Armstrong WR, Kishan AU, Booker KM, Hope TA, Fendler WP, Elashoff D, Nickols NG, Czernin J. Update from PSMA-SRT Trial NCT03582774: A Randomized Phase 3 Imaging Trial of Prostate-specific Membrane Antigen Positron Emission Tomography for Salvage Radiation Therapy for Prostate Cancer Recurrence Powered for Clinical Outcome. Eur Urol Focus. 2021 Mar; 7(2):238-240.  View on PubMed
  18. Hope TA. From Compassionate Use to Phase 3 Trial: The Impact of Germany's PSMA-617 Literature. J Nucl Med. 2020 12; 61(Suppl 2):255S-256S.  View on PubMed
  19. Hope TA. Updates to the Appropriate-Use Criteria for Somatostatin Receptor PET. J Nucl Med. 2020 12; 61(12):1764.  View on PubMed
  20. Borno HT, Kuo Lin T, Odisho AY, Desai A, Koshkin V, Werner K, Legaspi N, Bucknor M, Bell A, Zhang S, Hope TA. Evaluating determinants of receipt of molecular imaging in biochemical recurrent prostate cancer. Cancer Med. 2021 01; 10(1):62-69.  View on PubMed

Go to UCSF Profiles, powered by CTSI